Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Vaccines
•
Allergy & Immunology
•
Primary Care
How long do you counsel patients to wait after rituximab therapy before getting live vaccines?
Related Questions
Does splitting the dose of a vaccine during an observed administration affect the efficacy of the vaccine response?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?
How often do you monitor the eosinophil count after initiating anti-IL5 therapy for HAE?
Do you give additional pneumococcal vaccines after a dose of PCV20 in patients with asplenia?
What are your recommendations for managing perivascular dermatitis with eosinophils unresponsive to high-dose antihistamines, a prednisone taper, and topical steroids?
Do you continue shots when a patient transfers under your care and has been receiving less than effective doses of AIT, but insist they have been effective?
When would you pursue genetic testing for severe recalcitrant atopic dermatitis?
Are there any concerns with live vaccine innoculation and patients who are on denosumab?
How do you discuss the overlap of POTS, Ehlers-Danlos and MCAS with patients?
